Purpose: The integrin α v β 6 is overexpressed in a variety of aggressive cancers and serves as a prognosis marker. This study describes the conjugation, radiolabeling, and in vitro and in vivo evaluation of four chelators to determine the best candidate for 64 Cu radiolabeling of A20FMDV2, an α v β 6 targeting peptide. Procedures: Four chelators were conjugated onto PEG 28 -A20FMDV2 (1): 11-carboxymethyl-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4-methanephosphonic acid (CB-TE1A1P), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and 4, 4′-((3,6,10,13,16,19-hexazazbicyclo[6.6.6]ico-sane-1,8-diylbis(aza-nediyl)) bis(methylene)dibenzoic acid (BaBaSar). All peptides were radiolabeled with 64 Cu in ammonium acetate buffer at pH 6 and formulated to pH 7.2 in PBS for use. The radiotracers were evaluated using in vitro cell binding and internalization assays and serum stability assays. In vivo studies conducted include blocking, biodistribution, and small animal PET imaging. Autoradiography and histology were also conducted. Results: All radiotracers were radiolabeled in good radiochemical purity (995 %) under mild conditions (37-50°C for 15 min) with high specific activity (0.58-0.60 Ci/μmol). All radiotracers demonstrated α v β 6 -directed cell binding (946 %) with similar internalization levels (923 %). The radiotracers 64 Cu-CB-TE1A1P-1 and 64 Cu-BaBaSar-1 showed improved specificity for the α v β 6 positive tumor in vivo over 64 Cu-DOTA-1 and 64 Cu-NOTA-1 (+/− tumor uptake ratios-3.82 +/-0.44, 3.82±0.41, 2.58±0.58, and 1.29±0.14, respectively). Of the four radiotracers, 64 Cu-NOTA-1 exhibited the highest liver uptake (10.83±0.1 % ID/g at 4 h). Conclusions: We have successfully conjugated, radiolabeled, and assessed the four chelates CB-TE1A1P, DOTA, NOTA, and BaBaSar both in vitro and in vivo. However, the data suggests no clear "best candidate" for the 64 Cu-radiolabeling of A20FMDV2, but instead a trade-off between the different properties (e.g., stability, selectivity, pharmacokinetics, etc.) with no obvious effects of the individual chelators.
Introduction
T he integrin α v β 6 is an epithelial-specific receptor that is emerging as a biologically and clinically relevant target for the molecular imaging of cancer [1] . This integrin is not expressed in the vast majority of healthy adult epithelium but has been shown to be significantly upregulated in a variety of cancers including oral squamous cell carcinoma, intestinal gastric carcinoma, ovarian cancer, and pancreatic ductal adenocarcinoma [2] [3] [4] [5] . Additionally, it serves as a prognostic indicator with high levels of expression correlating with poor patient prognosis [6, 7] . A molecular imaging agent that targets the integrin α v β 6 could lead to new diagnostic and therapeutic strategies to improve the overall prognosis of the disease [8, 9] .
Imaging agents in the form of radiolabeled peptides have been used to image α v β 6 since they are relatively easy to synthesize with flexibility for chemical modifications while maintaining high binding affinity and specificity [10] [11] [12] [13] . We have previously shown that the 20-amino acid peptide A20FMDV2 can selectively target α v β 6 in a human tumor xenograft mouse model using the cell line DX3puroβ6, a human melanoma cell line expressing α v β 6 [14] . We have also shown that the addition of a monodisperse polyethylene glycol (PEG) polymer onto A20FMDV2 improves its pharmacokinetics and in vivo stability [15] . A20FMDV2 has been conjugated to 4,11-bis(carboxymethyl)-1,4,8,11-tetraaza-bicyclo[6.6.2]hexadecane (CB-TE2A) and monocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for radiolabeling with copper-64 to make the radiotracer more suitable for therapy as 64 Cu has both β + (20 %) and β − (37 %) emissions [16, 17] . While this work showed successful radiolabeling and small animal imaging with PET (positron emission tomography), both peptides exhibited high kidney retention and the CB-TE2A-conjugated peptide required high temperatures for 64 Cu incorporation, leaving much room for optimization for both radiolabeling and pharmacokinetics.
This study evaluates four 64 Cu chelators and their effects on the in vitro and in vivo properties of the pegylated A20FDMV2 peptide: 11-carboxymethyl-1,4,8,11-tetraazabicyclo[6.6.2] hexadecane-4-methanephosphonic acid (CB-TE1A1P), DOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and 4,4′-( (3,6,10,13,16,19-hexazazbicyclo[6.6.6 ]ico-sane-1,8-diylbis (aza-nediyl))bis(methylene)dibenzoic acid (BaBaSar). CB-TE1A1P is a cross-bridged macrocycle with a methane phosphonic acid pendant arm that can be radiolabeled under mild conditions while exhibiting high kinetic stability when conjugated to the peptidomimetic LLP2A [18] . DOTA and NOTA are both widely used, commercially available chelators.
BaBaSar is a carboxyl-functionalized sarcophagine cage-based chelator that can also be radiolabeled under mild conditions and exhibited lower liver uptake compared to DOTA when conjugated to a cyclic RGD peptides [19, 20] . Here we describe the conjugation, radiolabeling, and in vitro and in vivo characterizations of all four tracers to determine the best candidate for 64 Cu radiolabeling of pegylated A20FMDV2.
Materials and Methods
Solvents and chemicals were purchased from Aldrich (Milwaukee, WI, USA) unless stated otherwise and used without further purification. 9-Fluorenylmethoxycarbonyl (Fmoc)-protected amino acids, Novasyn TGR resin, Fmoc-NH-PEG 28 -carboxylic acid, and coupling reagents were purchased from NovaBiochem (San Diego, CA, USA) or GL Biochem (Shanghai, China). The chelators DOTA(tBu) 3 and NOTA(tBu) 2 were purchased from CheMatech (Dijon, France). A reverse-phase high-performance liquid chromatography (HPLC; Beckman Coulter Gold HPLC) system was used to analyze and purify the peptides. The system has an ultraviolet absorbance detector (220 nm) and a radioactivity detector (photomultiplier tube; Flow-Count radio-HPLC system, Bioscan, Washington DC, USA) connected in series. The mobile phase was 0.05 % trifluoroacetic acid in water (v/v; solvent A) and 100 % acetonitrile (solvent B). For the analytical HPLC: Phenomenex Jupiter 4μ Proteo 90 Å column (250×4.6 mm, 4 μm), solvent B isocratic 9 % for 2 min, then a linear gradient to 81 % over 30 min with a flow rate of 1.5 ml/ min. For the semi-preparative HPLC: Phenomenex Jupiter 10 μ Proteo 300 Å column (250×10 mm, 10 μm), solvent B isocratic 9 % for 2 min, then a linear gradient to 81 % over 30 min at a flow rate of 3 ml/min. Mass spectrometry was performed using an ABI 4700 matrix-assisted laser desorption-ionization time of flight/time of flight (MALDI TOF/TOF) spectrometer (Applied Biosystems, Foster City, CA, USA).
The cell lines DX3puro and DX3puroβ6 were described previously [14] . The cells were cultured at 37°C and 5 % CO 2 in Dulbecco's Modified Eagle's Medium (DMEM) containing 10 % fetal bovine serum and 1 % penicillin-streptomycin-glutamine (Gibco/Life Technologies, Grand Island, NY, USA). All immunohistochemistry supplies were purchased from Vector Labs (Burlingame, CA, USA) unless otherwise stated.
Cell labeling and biodistribution samples were analyzed with a Wizard 1470 gamma counter (Perkin-Elmer, Waltham, MA, USA). Small-animal PET scans were acquired on a Siemens Inveon DPET scanner and computed tomography (CT) scans on a combined high-resolution Inveon SPECT/CT system (Siemens Medical Solutions USA, Knoxville, TN, USA). The data was processed with Siemens Inveon Research Workplace software.
Peptide Synthesis
The 20-mer A20FMDV2 peptide was manually synthesized on Novasyn TGR resin using three molar equivalents of amino acids 568 L.Y. Hu et al.: 64 and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and six molar equivalents of Ndiisopropyslethylamine (DIPEA) for 1.5-h coupling time at room temperature followed by 30 min total of Fmoc deprotection with 20 % piperidine in N,N-dimethylformamide (DMF). The peptide was modified using Fmoc-PEG 28 -COOH as reported previously [16] . The chelators DOTA(tBu) 3 and NOTA(tBu) 2 were coupled onto the pegylated peptide (1) using 3 molar equivalents for 3 h at room temperature to create the tracers DOTA-1 and NOTA-1, respectively. CB-TE1A1P was similarly coupled on solid phase using 6 molar equivalents overnight at room temperature to yield CB-TE1A1P-1. Peptide conjugates on solid phase were cleaved from the resin using trifluoroacetic acid/1,2-ethanedithiol/ triisopropyl-silane/water 94:2.5:1:2.5 (v/v/v/v) to yield the Cterminus amides. The crude peptide conjugates were dissolved in water and washed three times with diethyl ether before analysis with HPLC and MALDI. BaBaSar was conjugated onto the cleaved pegylated peptide with Lys(ivDde) in solution phase to create BaBaSar-1 ( Fig. 1) . Briefly, the carboxylic acid on BaBaSar was activated by ethyl(dimethylaminopropyl) carbodiimide and sulfo-Nhydroxysulfosuccinimide to form a BaBaSar-Osu intermediate.
Without purification, BaBaSar-Osu was conjugated with the free amino group on the peptide. The ivDde protecting group was later removed using 2 % hydrazine in DMF (v/v) for 30 min at room temperature, followed by HPLC and MALDI. All peptide conjugates were purified using semipreparative HPLC prior to radiolabeling.
Radiochemical Synthesis
Copper-64 was obtained from Washington University School of Medicine in the form 64 CuCl 2 (5-10 μl in 0.5 M HCl) and diluted in ammonium acetate buffer (pH 6). All four peptide conjugates (CB-TE1A1P-1, DOTA-1, NOTA-1, and BaBaSar-1) were dissolved in sterile ammonium acetate buffer before radiolabeling to a final concentration of 10 mg/ml. Each peptide (0.25 mg, 25 μl) was added to 64 Cu-acetate (4-7 mCi) with a final volume of 50-60 μl in 0.1 M ammonium acetate buffer (pH 6). All reactions were carried out at 37°C for 15 min, except for CB-TE1A1P-1, which was radiolabeled at 50°C for 15 min. The radiochemical purity (RCP) of each reaction was determined using HPLC after quenching an aliquot of the reaction with 5 mM ethylenediaminetetraacetic acid (EDTA, 150 μl).
In Vitro Experiments
Cell Binding Cell lines were analyzed with flow cytometry before experiments to confirm integrin expression levels. Cell binding experiments were carried out as previously described [21] . Briefly, 4 μCi of each radiotracer was added to a cell suspension of either DX3puro (α v β 6 negative) or DX3puroβ6 (α v β 6 positive) cells in serum-free DMEM (pH 7.2; 3.75×10 6 cells in 50 μl) in Eppendorf tubes pretreated with bovine serum albumin (5 % wt/v in PBS) to block non-specific binding. The mixture was incubated at room temperature with regular agitation for 60 min before washing with serum-free DMEM. Following centrifugation (130×g, 3 min), the supernatant was separated from the cell pellet. The pellet underwent an additional wash with 0.5 ml serum-free DMEM, and the supernatants were combined before the fraction of bound activity was determined with a gamma counter. To determine the fraction of internalized radiotracer, the cells were treated with cold acidic wash buffer (pH 2.5, 300 μl) for 5 min at 4°C, centrifuged (130×g, 3 min), and washed with 0.3 ml cold PBS. The supernatants were then combined and the cells were subsequently re-suspended in 0.6 ml PBS. The internalized fraction was detected with a gamma counter and expressed as a percentage of total activity. Serum Stability Mouse serum was combined with an aliquot of the formulated radiotracer (100-200 μCi) and incubated at 37°C. L.Y. Hu et al.: 64 Cu-Radiolabeled A20FMDV2 569
At time points of 1, 4, and 24 h, aliquots (100-200 μl) were taken from the sample, mixed with absolute ethanol (500 μl, 4°C), and centrifuged (2,300×g, 2.5 min) to precipitate out serum proteins. The supernatant was challenged with 5 mM EDTA solution (300 μl) before HPLC analysis to determine the fraction of intact radiotracer.
In Vivo Experiments
Female nu/nu nude mice (6-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA) and handled according to the UC Davis Institutional Animal Care and Use Committee. DX3puro and DX3puroβ6 cells ( 3×10 6 ) in 100 μl serum-free DMEM were implanted subcutaneously into opposite shoulder flanks and allowed to grow for approximately 3 weeks (0.5-1 cm in diameter). All cells were evaluated with flow cytometry before injection to confirm integrin expression levels. Food and water were available ad libitum.
Small-Animal Imaging
Aliquots of the formulated radiotracer (150-250 μCi in 50-60 μl) in isotonic solution (pH 7.2) were injected intravenously (i.v.) via a catheter into the tail vein of mice (n=4/time point/radiotracer) anesthetized with 2-3 % isoflurane in medical grade oxygen. Animals were imaged two at a time, side by side in a feet-first prone position on the scanner bed. For blocking studies, NH 2 -PEG 28 -A20FMDV2 (30 mg/kg as a 10 mg/ml solution in PBS) was injected 10 min before the formulated radiotracer. Anesthesia was maintained during the scan at 1.5-2.5 % isoflurane in medicalgrade oxygen. Static, single-frame 15-min emission scans were acquired at time points of 1, 4, and 24 h post-injection (p.i.). A cobalt-57 transmission scan for attenuation correction and a CT scan for anatomical reference were also acquired.
Autoradiography and Histology
Each formulated radiotracer (1 mCi in 200 μl) was injected into the tail vein of a mouse (n=1/radiotracer). Following a 4-h conscious uptake time, the mouse was anesthetized and sacrificed. Both tumors and the kidneys were dissected and frozen in freezing medium (Tissue-Tek, Sakura Finetek). The tissues were sectioned using a Leica CM1850 cryostat (Leica Microsystems) in 20-μm slices and exposed to a storage phosphor screen (GE Healthcare) overnight. The screen was read with a Storm 860 phosphorimager (GE Healthcare) using a 50-μm resolution.
For immunohistochemistry staining, tumors were sectioned into 5-μm slices and mounted onto glass slides (3 sections/slide). The slides were fixed with periodate-lysine-paraformaldehyde, washed with PBS, and outlined with an ImmEdge pen. Endogenous peroxidase was blocked using 3 % hydrogen peroxide and 0.3 % normal horse serum in PBS. To block non-specific uptake, 2.5 % normal horse serum was used prior to antibody binding steps. The antibodies used were an anti-integrin β6 antibody (Santa Cruz Biotechnologies, Inc., Dallas, TX, USA) for 1 h at room temperature and a subsequent HRP-labeled anti-goat antibody for 30 min at room temperature. Negative controls were performed for each tumor omitting the primary antibody. The substrate used was ImmPACT DAB and the enzymatic reaction was stopped after 10 min with water. Mayer's hematoxylin was used as the background stain (30 s, room temperature) and washed with water. The slides were then dehydrated in ethanol (70, 95, and 100 %), followed by xylene (100 %, twice) and permanently mounted with DePEX mounting medium.
Biodistribution
Aliquots of the formulated radiotracer (50 μCi in 50-60 μl isotonic solution) were injected into the tail vein followed by conscious uptake periods of 1, 4, and 24 h. At each time point, the mice (n=3/ time point/radiotracer) were anesthetized and sacrificed. The tissues were collected, rinsed with PBS, and the radioactivity of each measured with a gamma counter. Radioactivity concentrations were calibrated, decay-corrected, and expressed as percent of injected dose per gram of tissue (% ID/g).
Urine Analysis
Urine samples (10-100 μl, n =1/time point/radiotracer) were collected during biodistribution studies at 1 and 4 h p.i. and analyzed for degradation by radioHPLC. Proteins were precipitated with absolute ethanol (500 μl, 4°C) and removed by centrifugation at 2,300×g for 10 min. All samples were challenged with 5 mM EDTA solution (300 μl) before HPLC analysis.
Statistical Analysis
All statistical data are reported as mean±standard deviation (SD). Paired, two-tailed Student's t tests were used to evaluate statistical significance, where p G0.05 was considered statistically significant.
Results

Peptide Synthesis
The tracers were prepared as described and obtained in high purity (≥95 %). The analytical data for the peptides are as follows: CB-TE1A1P-1, HPLC retention time (R t )=16. 
Radiochemical Synthesis
All peptide conjugates were incubated with 64 Cu-acetate at 37°C for 15 min with the exception of CB-TE1A1P-1 which was radiolabeled at 50°C for 15 min. The RCP was 998 %, 995 %, 996 %, and 997 % with a specific activity of 0.58 Ci/ μmol, 0.59 Ci/μmol, 0.58 Ci/μmol, and 0.60 Ci/μmol for 64 Cu-CB-TE1A1P-1, 64 Cu-DOTA-1, 64 Cu-NOTA-1, and 64 Cu-570 L.Y. Hu et al.: 64 Cu-Radiolabeled A20FMDV2
BaBaSar-1, respectively. The results are summarized in Table 1 . All radiotracers were formulated to pH 7.2 in PBS without further purification.
Cell Binding
Cell binding assays were used to evaluate the ability of the radiotracers to bind α v β 6 in vitro. Integrin expression in the cell lines DX3puro (α v β 6 negative) and DX3puroβ 6 (α v β 6 positive) were confirmed through flow cytometry. The binding to α v β 6 -positive DX3puroβ 6 cells were 65.3±1.8 % for 64 Cu-CB-TE1A1P-1, 60.9±1.1 % for 64 Cu-DOTA-1, 46.6±1.3 % for 64 Cu-NOTA-1, and 58.3±1.8 % for 64 Cu-BaBaSar-1. All radiotracers demonstrated low binding to the α v β 6 -negative Dx3puro cells (G12 % binding). The percent internalized relative to the amount bound to the α v β 6 -positive DX3puroβ 6 cells were 47.4±0.6 % for 64 Cu-CB-TE1A1P-1, 46.2±1.7 % for 64 Cu-DOTA-1, 40.7±3.5 % for 64 Cu-NOTA-1, and 23.8±1.7 % for 64 Cu-BaBaSar-1 (Fig. 2) .
Serum Stability
All radiotracers were incubated in mouse serum at 37°C for 24 h with aliquots taken out at each time point. After 24 h, all radiotracers showed significant degradation with 64 Cu-NOTA-1 exhibiting the highest amount of EDTAcomplexed free copper (Fig. 3a) .
Small-Animal Imaging and Biodistribution
In vivo evaluation of 64 Cu-CB-TE1A1P-1, 64 Cu-DOTA-1, 64 Cu-NOTA-1, and 64 Cu-BaBaSar-1 by small-animal PET and biodistribution studies revealed selective uptake in the α v β 6 -positive tumor over the α v β 6 -negative tumor for three of the four radiotracers and renal clearance as the main route of elimination from the body for all radiotracers. At 4 h p.i., all radiotracers except 64 Cu-NOTA-1 showed a statistically significant difference in uptake between the positive and negative tumors ( 64 Cu-CB-TE1A1P-1-p=0.013, 64 Cu-DOTA-1-p=0.003, 64 Cu-NOTA-1-p=0.475, and 64 Cu-BaBaSar-1-p=0.015) (Fig. 4a-d) . In terms of absolute % ID/g numbers, 64 Cu-NOTA-1 demonstrated the highest uptake in the α v β 6 -positive tumor (2.44±0.76 % ID/g at 4 h p.i.) and 64 Cu-DOTA-1 demonstrated the lowest uptake in the α v β 6 -positive tumor (1.11±0.58 % ID/g at 4 h p.i.) (Table 2 ). However, positive to negative tumor ratios reveal that 64 Cu-CB-TE1A1P-1 and 64 Cu-BaBaSar-1 had the highest specificity for the α v β 6 -positive tumor (3.82±0.44 and 3.82±0.41, respectively) (Fig. 4e) . All radiotracers exhibited high kidney uptake at 4 h p.i. with 64 Cu-BaBaSar-1 (196.9±54.5 % ID/g) and 64 Cu-CB-TE1A1P-1 (122.7±25.8 % ID/g) having higher kidney uptake than 64 Cu-DOTA-1 (69.2±11.8 % ID/g) and 64 Cu-NOTA-1 (69.12±19.5 % ID/g) (Fig. 5b ). All four radiotracers had relatively low liver uptake with 64 Cu-NOTA-1 having the highest liver uptake (10.8±1.1 % ID/g) and 64 Cu-CB-TE1A1P-1 having the lowest liver uptake and that stayed consistently low at all time points (1 h-1.27±0.17 % ID/g, 4 h-1.45±0.14 % ID/g, 24 h-0.92±0.8 % ID/g) (Fig. 5c) . Both 64 Cu-DOTA-1 (1 h-2.04±0.33 % ID/g, 4 h-1.41± 0.57 % ID/g, 24 h-3.13±0.43 % ID/g) and 64 Cu-BaBaSar-1 (1 h-1.54 ± 0.23 % ID/g, 4 h-2.61± 0.05 % ID/g, 24 h-3.41±0.35 % ID/g) showed a slightly increasing trend from 1 to 24 h p.i. Uptake in other non-target organs such as gallbladder (24 h- 64 Cu-CB-TE1A1P-1, 1.84±1.15 % ID/g; 64 Cu-DOTA-1, 2.26±0.35 % ID/g; 64 Cu-NOTA-1, 1.45± 0.24 % ID/g; and 64 Cu-BaBaSar-1, 3.43±0.36 % ID/g) and stomach (24 h- 64 Cu-CB-TE1A1P-1, 7.35±1.48 % ID/g; 64 Cu-DOTA-1, 5.34±0.96 % ID/g; 64 Cu-NOTA-1, 1.30± 0.22 % ID/g; and 64 Cu-BaBaSar-1, 11.20±1.17 % ID/g) demonstrated clearance with time (Online Resources ESM 1-4). 64 Cu-DOTA-1 and 64 Cu-NOTA-1 exhibited stable tumor/blood ratios (approximately 3-5) at all time points while 64 Cu-CB-TE1A1P-1 exhibited an initial increase from 1 to 4 h p.i.
(1 h-3.98±1.99, 4 h-8.25±1.49, p=0.041) that leveled off at 24 h p.i. Interestingly, 64 Cu-BaBaSar-1 exhibited steady tumor/ Table 1 . Analytical data and reaction parameters for the four radiotracers 64 Cu-CB-TE1A1P-1 64 Cu-DOTA-1 64 Cu-NOTA-1 64 Cu-BaBaSar-1 (Fig. 5d) . Tumor/muscle ratios reveal that 64 Cu-DOTA-1 was the only radiotracer to demonstrate an overall upwards trend through the time points (1 h-1.76±0.49, 4 h-2.76±0.63, 24 h-4.23±0.29), the others demonstrated fairly stable ratios at all three time points (Fig. 5e) .
After a pre-injection of NH 2 -PEG 28 -A20FMDV2, all tracers except 64 Cu-NOTA-1 showed a statistically significant reduction in binding to the positive tumor at 24 h p.i, 64 Cu-CB-TE1A1P-1 (without blocking-0.89±0.21 % ID/g; with blocking-0.14 ± 0.15 % ID/g, p = 0.023), 64 Cu-DOTA-1 (without blocking-1.28±0.30 % ID/g, with blocking-0.51±0.14 % ID/g, p=0.046), 64 Cu-NOTA-1 Cu-BaBaSar-1 (without blocking-2.23±0.63 % ID/g, with blocking-0.69±0.03 % ID/g, p=0.046) (Fig. 5a ).
Urine Analysis
In urine, all radiotracers showed significant degradation at 1 h p.i. ( 64 Cu-CB-TE1A1P-1-1 % intact, 64 Cu-DOTA-1-6.6 % intact as a double peak, 64 Cu-NOTA-1-15.9 %, and 64 Cu-BaBaSar-1-3 % intact). All four radiotracers demonstrated similar degradation in that they all showed the formation of a new, more polar metabolite with a 2-3 min faster retention time on radioHPLC than the parent radiotracer (Fig. 3b) .
Autoradiography and Histology
Autoradiography slices of the positive and negative tumor further confirm selective binding to the α v β 6 -positive xenograft Cu-BaBaSar-1 (individually scaled). These values were used to calculated e positive to negative tumor uptake ratios. Uptake values are represented as % ID/g. P values were determined using paired, two-tailed Student t tests. Table 2 . A summary of results from in vitro and in vivo studies 64 Cu-CB-TE1A1P-1 64 Cu-DOTA-1 64 Cu-NOTA-1 64 Cu-BaBaSar-1
Serum stability (24 h) G45 % G40 % G35 % 14.0 % Urine metabolites (%intact at 4 h) 0 % 0 % -3 % Positive tumor uptake (4 h at all times with 64 Cu-NOTA-1 exhibiting the smallest difference in uptake between the positive and negative tumors (Fig. 6a, b) . The images reveal the majority of the uptake to be around the tumor margins. Immunohistochemistry staining of the positive tumor for the integrin α v β 6 confirmed high expression around the margins of the tumors with no expression at the necrotic core (Fig. 6c) . Additional autoradiography slices of the kidney reveal uptake within the renal cortex (data not shown).
Discussion
The integrin α v β 6 plays an important role in the imaging of cancer with PET [22] . Although not expressed in the majority of healthy adult epithelium, this integrin is upregulated in various cancers and serves as a prognosis indicator due to its overexpression in aggressive cancers [3, 7, 9] . Thus, it is desirable to have a non-invasive imaging probe to detect α v β 6 -positive tumors as it can provide valuable information for both diagnostic and treatment planning. Here, we described the 64 Cu radiolabeling of the pegylated A20FMDV2 peptide, a peptide shown to target the integrin α v β 6 , via four different chelators. CB-TE1A1P is a cross-bridged cyclam-based macrocycle featuring a phosphonate pendant arm that can readily complex copper(II) under mild conditions at high specific activity [18, 23] . DOTA and NOTA are two commercially available, widely used chelators for a variety of different small molecules [24] . BaBaSar is a carboxyl-functionalized sarcophagine cage chelator with two benzoic acid moieties that has been shown to radiolabel under mild conditions while exhibiting high stability in vivo [20] .
All four tracers were successfully radiolabeled with copper-64 on PEG 28 -A20FMDV2 in good radiochemical purity under mild conditions. However, CB-TE1A1P-1 required a higher temperature to radiolabel at greater than 95 % RCP. This could be due to slower kinetics of copper complexation after the carboxymethyl pendant arm was conjugated onto the peptide. Previously, this chelator was radiolabeled on the peptidomimetic LLP2A via a hydrophilic linker and was able to radiolabel after 60 min at room temperature [18] . We observed approximately 45 % RCP after 15 min at 37°C indicating the ability to complex copper at the same temperature as other the chelatorconjugated A20FMDV2 peptides but demanding a longer incubation period.
It has previously been demonstrated that the addition of bulky chelators or prosthetic groups can affect the binding, internalization, and metabolism of receptor targeting peptides [25] [26] [27] [28] . The in vitro cell binding and internalization assays revealed that all four radiotracers show binding directed towards the integrin α v β 6 with fairly comparable internalization levels, indicating that the addition of a chelator and the radiolabeling with 64 Cu did not drastically affect the binding potential of the PEG 28 -A20FMDV2 peptide.
The four radiotracers showed varied stability in serum and urine. In serum, all radiotracers showed significant degradation with new metabolites forming after 24 h. Since all four chelators were conjugated onto the peptide via a carboxylic acid moiety, no obvious differences exist to account for variability in their in vivo stability. The urine metabolite studies revealed that all radiotracers degraded in a similar fashion to the previously studied 4-[ 28 -A20FMDV2) in that they degraded into one major metabolite that is more polar [21] .
Although high positive-to-negative tumor uptake ratios were observed for 64 Cu-CB-TE1A1P-1 and 64 Cu-BaBaSar-1, there was significantly unexpected higher kidney uptake than 64 Cu-DOTA-1 and 64 Cu-NOTA-1. Previous studies with a derivative of BaBaSar called AmBaSar (a sarcophagine cage with one benzoic acid) and DOTA on a cyclic RGD peptide in a mouse malignant glioma model showed G5 % ID/g uptake in the kidneys [19] . When CB-TE1A1P was tested on the 
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L.Y. Hu et al.: 64 Cu-Radiolabeled A20FMDV2 peptidomimetic LLP2A in comparison to CB-TE2A, both conjugates also demonstrated low kidney uptake levels (G5 % ID/g) [18] . Similarly, when CB-TE1A1P was tested on the somatostatin agonist Y3-TATE, the kidney uptake level remained consistently low at 5 % ID/g at all time points (up to 24 h p.i.) [23] . These previous instances of low kidney uptake all occur on tracers demonstrating high metabolic stability [29] [30] [31] . Since the urine metabolite data reveals one major radioactive metabolite for all four radiotracers in this study, it is likely that the metabolite is accumulating within the kidney. However, [
18 F]-FBA-PEG 28 -A20FMDV2 quickly clears from the kidney (1 h-24.7±4.8 % ID/g, 4 h-2.7±0.8 % ID/g) [16] . This result shows that while the addition of a bulky chelator group onto the peptide is not drastically influencing its binding affinity, it is clearly affecting how the peptide behaves in vivo and the binding of the metabolites formed. To further emphasize this point, when PEG 28 -A20FMDV2 was labeled using Al[ 18 F]-NOTA, which is equivalent to a [ 18 F]-chelate, the radiotracer also exhibits extremely high and increasing kidney uptake in a pancreatic tumor mouse model [32] . These data suggest that the addition of any chelator onto this peptide alters its pharmacokinetic behavior. At this time, the identity of the major metabolite of each radiotracer has not been confirmed but is likely to be a 64 Cu-chelate-peptide fragment [33] . Future efforts are underway to stabilize the PEG 28 -A20FMDV2 peptide.
To demonstrate specific binding in vivo, blocking studies with cold peptide were performed. A decrease in the uptake of the radiotracer by the positive tumor is usually observed, such as with the statistically significant difference observed with 64 Cu-CB-TE1A1P-1, 64 Cu-DOTA-1, and 64 Cu-BaBaSar-1. However, 64 Cu-NOTA-1 exhibited an increase in binding to the α v β 6 -positive tumor. The increase in binding to the α v β 6 -positive tumor with 64 Cu-NOTA-1 was surprising and the cause of it is not immediately known. While there is precedent in the literature indicating that uptake in organs can be affected by the overall mass injected [34, 35] , this needs to be further investigated before any conclusions can be drawn. L.Y. Hu et al.: 64 Cu-Radiolabeled A20FMDV2 575
The tumor/blood ratio for 64 Cu-BaBaSar-1 significantly dropped from 4 to 24 h p.i., indicating a dramatic increase in blood concentration. This was unexpected since 64 CuBaBaSar-1 was the only radiotracer to have any fraction intact at 24 h in the urine. Since the liver uptake also shows an increasing trend, this could be attributed to free 64 Cu being released by the chelator. While liver uptake was relatively low among all of the radiotracers, 64 Cu-CB-TE1A1P-1 demonstrated the lowest liver uptake and was the only radiotracer whose liver uptake did not increase over time. This demonstrates the in vivo inertness of the 64 Cu-CB-TE1A1P conjugate, as accumulation in the liver can be attributed to transchelation and binding of 64 Cu to proteins such as superoxide dismutase [36] . 64 Cu-NOTA-1 demonstrated the highest liver uptake. 64 Cu-DOTA-1 was the only radiotracer to exhibit increasing tumor/muscle ratios; however, the absolute % ID/g numbers reveal this is an effect of muscle clearance rather than an increase in tumor accumulation.
This study aimed to find the ideal 64 Cu chelator for the radiolabeling of PEG 28 -A20FMDV2. While the choice of chelator can affect different properties such as stability and selectivity in vivo, some of the pharmacokinetic effects are clearly attributed to the peptide itself. Ultimately, notable differences exist with the addition of any chelator to this peptide in comparison to the [ 18 F]-peptide previously radiolabeled with the FBA prosthetic group.
Conclusion
In summary, the peptide PEG 28 -A20FMDV2 was evaluated and characterized with four chelators: CB-TE1A1P, DOTA, NOTA, and BaBaSar. Compared to the two commercially available chelators, the two newly developed chelators, CB-TE1A1P and BaBaSar, showed improved specificity for the α v β 6 -positive tumor when conjugated onto PEG 28 -A20FMDV2, but they also showed the highest kidney retention. Previous data show this is an inherent property of the peptide metabolizing in vivo, but the effect is compounded by the addition of a chelator, as this alters the binding properties of the metabolite compared to the identical peptide labeled with a fluorine-18 prosthetic group such as FBA. All four radiotracers demonstrated relatively low liver uptake. The data suggests no clear "best candidate" for the 64 Cu radiolabeling of A20FMDV2, but instead a trade-off between the different properties (e.g., stability, selectivity, pharmacokinetics, etc.) with no obvious effects of the individual chelators. There are several Cu(II) chelators available from commercial sources and reported in the literature, and there is continued development of new chelators, but clearly many factors influence the selection for radiolabeling and subsequent use as imaging or therapeutic agents. Future studies will focus on working with a stabilized version of the A20FMDV2 peptide to achieve lower kidney uptake and faster renal clearance. This work demonstrates that several 64 Cu-radiolabeled A20FMDV2 radiotracers can successfully target the integrin α v β 6 and serve as an imaging agent.
